ClinicalTrials.gg
Not yet recruitingNCT06384859Updated Apr 25, 2024

Effectiveness of Extracorporeal Shockwave Therapy Combined With Platelet-rich Plasma in the Treatment of Chronic Insertional Achilles Tendinopathy

A Phase 4 interventional study of ESWT and PRP in Insertional Achilles Tendinopathy, sponsored by Mahidol University. Not yet recruiting at 1 site in Thailand. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-25.

Sponsored by Mahidol University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing platelet rich plasma in Tendinopathy — 2 open to participants now, 4 under way, none of them phase 3. platelet rich plasma · Tendinopathy.

Planned enrollment
5th of 14
94 · median 62
Started
2024
the only one that year
Phase 4
4 of 14
1 open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
Mahidol University

Among the 14 studies testing platelet rich plasma in Tendinopathy, this one is the 5th largest by planned enrollment, is the only one that started in 2024, is one of 4 in phase 4, and was the 12th registered.

Tendinopathy

397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

2 of the 14 studies testing platelet rich plasma in Tendinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About platelet rich plasma

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 47 Tendinopathy studies recruiting now, 17 (36%) set no upper age limit and 23 (49%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing platelet rich plasma in Tendinopathy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the effectiveness of extracorporeal shockwave(ESWT) combined with platelet-rich plasma(PRP) to treat chronic insertional tendinopathy. The main questions it aims to answer are:

Does ESWT combined with PRP treatment reduce the symptom and improve functional score after treatment? What medical complication do participants have when receive the treatment?

Researchers will compare ESWT combined with PRP to ESWT treatment alone to see if ESWT combined with PRP works to treat chronic insertional tendinopathy.

Participants will:

  • Receive ESWT once a week for 4 weeks then receive PRP injection at a week later or ESWT once a week for 4 weeks
  • Visit the clinic at 6 weeks, 3 months, 6 months and 1 year after treatment for checkups and record functional score
03

Conditions studied

  • Insertional Achilles Tendinopathy

Browse trials for

Keywords

  • chronic insertional Achilles tendinopathy
  • extracorporeal shockwave therapy
  • platelet rich plasma
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with insertional Achilles tendinopathy
  • Had symptom more than 6 months
  • Failed other standard conservative treatment (rest, medication, activity modification, stretching exercise, and heel lift orthosis)

Exclusion criteria

Exclusion Criteria:

  • Receive injection at the Achilles insertion
  • History of infection around ankle and heel
  • Has neurological deficit
  • Has a for ESWT(hemophilia, coagulopathy or foot and ankle )
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    ESWT + PRP

    Receive ESWT once a week for 4 weeks and PRP injection at a week later

    Device: ESWT · Biological: PRP

  • Active comparator
    ESWT

    Receive ESWT once a week for 4 weeks

    Device: ESWT

Interventions

  • DeviceESWT

    Receive ESWT once a week for 4 weeks

  • BiologicalPRP

    Receive PRP injection at week 5

06

What researchers measure

Primary outcomes

  1. VAS

    Visual Analogue Scale

    Time frame: 6 week, 3 months, 6 months and 1 year after treatment

Secondary outcomes

  1. VAS-FA

    Visual analogue scale foot and ankle

    Time frame: 6 week, 3 months, 6 months and 1 year after treatment

  2. FFI

    Foot functional index

    Time frame: 6 week, 3 months, 6 months and 1 year after treatment

  3. FAAM

    Foot and Ankle Ability Measure

    Time frame: 6 week, 3 months, 6 months and 1 year after treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2024; primary completion for May 2026, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
Apr 25, 2024
StartEst.
May 1, 2024
Primary completionEst.
May 1, 2026
CompletionEst.
May 1, 2027
Last update
Apr 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06384859
Lead sponsor
Mahidol University
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
May 1, 2024 (estimated)
Primary completion
May 1, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Apr 25, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion